1. Драпкина О.М., Самородская И.В., Старинская М.А., Бойцов С.А. Сравнение российских регионов по уровню стандартизованных коэффициентов смертности от всех причин и болезней системы кровообращения в 2006–2016 гг. Профилактическая медицина. 2018;21(4):4–12. DOI: 10.17116/profmed20182144
2. Концевая А.В., Драпкина О.М., Баланова Ю.А., Имаева А.Э., Суворова Е.И., Худяков М.Б. Экономический ущерб сердечно-сосудистых заболеваний в Российской Федерации в 2016. Рациональная фармакотерапия в кардиологии. 2018;14(2):156-66]. DOI: 10.20996/1819-6446-201814-2-156-166
3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393
4. Аверков О. В., Дупляков Д.В., Гиляров М.Ю., Новикова Н.А., Шахнович Р.М., Яковлев А.Н. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):251-310]. DOI: 10.15829/29/1560-4071-2020-4103
5. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. European Heart Journal. 2017;38(41):3056–65. DOI: 10.1093/eurheartj/ehx515
6. Addala S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). The American Journal of Cardiology. 2004;93(5):629–32. DOI: 10.1016/j.amjcard.2003.11.036
7. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R et al. A New Score for Risk Stratification of Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2012;5(11):1108–16. DOI: 10.1016/j.jcin.2012.07.011
8. Ran P, Yang JQ, Li J, Li G, Wang Y, Qiu J et al. A risk score to predict in-hospital mortality in patients with acute coronary syndrome at early medical contact: results from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) Project. Annals of Translational Medicine. 2021;9(2):167. DOI: 10.21037/atm-21-31
9. Hizoh I, Banhegyi G, Domokos D, Major L, Andrassy P, Andreka P et al. TCT-804 Comparative Validation of the ALPHA Score, a Novel Risk Model Including Vascular Access Site for Predicting 30-Day Mortality in Patients Treated with Primary PCI. Journal of the American College of Cardiology. 2018;72(13): B320–1. DOI: 10.1016/j.jacc.2018.08.2039
10. Al’Aref SJ, Singh G, van Rosendael AR, Kolli KK, Ma X, Maliakal G et al. Determinants of In‐Hospital Mortality Aſter Percutaneous Coronary Intervention: A Machine Learning Approach. Journal of the American Heart Association. 2019;8(5):e011160. DOI: 10.1161/JAHA.118.011160
11. Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F et al. Prediction of risk of death and myocardial infarction in the six months aſter presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. DOI: 10.1136/bmj.38985.646481.55
12. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–7. DOI: 10.1161/01.CIR.102.17.2031
13. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E et al. Prediction of Mortality Aſter Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC risk score. Journal of the American College of Cardiology. 2005;45(9):1397– 405. DOI: 10.1016/j.jacc.2005.01.041
14. Kirtane AJ, Sandhu P, Mehran R, McEntegart M, Cristea E, Bre
15. ner SJ et al. Association Between Intraprocedural Thrombotic Events and Adverse Outcomes Aſter Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial InfarctionSubstudy). The American Journal of Cardiology. 2014;113(1):36–43. DOI: 10.1016/j.amjcard.2013.08.034
16. Sabell T, Banaszewski M, Lassus J, Nieminen MS, Tolppanen H, Jäntti T et al. Prognostic impact of angiographic findings, procedural success, and timing of percutaneous coronary intervention in cardiogenic shock. ESC Heart Failure. 2020;7(2):768–73. DOI: 10.1002/ehf2.12637
17. Бессонов И.С., Сапожников С.С., Кузнецов В.А., Зырянов И.П., Дьякова А.О., Мусихина Н.А. и др. Регистр чрескожных коронарных вмешательств у пациентов с острым инфарктом миокарда с элевацией сегмента ST. Свидетельство о регистрации базы данных 2020621653, 11.09.2020. Заявка № 2020621535 от 02.09.2020]
18. Бессонов И.С., Кузнецов В.А., Горбатенко Е.А., Сапожников С.С., Зырянов И.П. Результаты чрескожных коронарных вмешательств у пациентов с острым инфарктом миокарда с подъемом сегмента ST в различных возрастных группах. Сибирский научный медицинский журнал. 2021;41(2):56-65]. DOI: 10.18699/SSMJ20210208
19. Haller PM, Jäger B, Farhan S, Christ G, Schreiber W, Weidinger F et al. Impact of age on short- and long-term mortality of patients with ST-elevation myocardial infarction in the VIENNA STEMI network. Wiener klinische Wochenschriſt. 2018;130(5–6):172–81. DOI: 10.1007/s00508-017-1250-7
20. Fach A, Bünger S, Zabrocki R, Schmucker J, Conradi P, Garstka D et al. Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention Analyzed by Age Groups (85 Years); (Results from the Bremen STEMI Registry). The American Journal of Cardiology. 2015;116(12):1802–9. DOI: 10.1016/j.amjcard.2015.09.022
21. Nielsen CG, Laut KG, Jensen LO, Ravkilde J, Terkelsen CJ, Kristensen SD. Patient delay in patients with ST-elevation myocardial infarction: Time patterns and predictors for a prolonged delay. European Heart Journal: Acute Cardiovascular Care. 2017;6(7):583–91. DOI: 10.1177/2048872616676570
22. Kheiri B, Osman M, Abdalla A, Haykal T, Chahine A, Gwinn M et al. Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Me-ta-Analysis of Randomized Controlled Trials. Cardiovascular Revascularization Medicine. 2019;20(9):744–51. DOI: 10.1016/j.car-rev.2018.11.005
23. Entezarjou A, Mohammad MA, Andell P, Koul S. Culprit vessel: impact on short-term and long-term prognosis in patients with ST-elevation myocardial infarction. Open Heart. 2018;5(2):e000852. DOI: 10.1136/openhrt-2018-000852
24. Ram P, Shah M, Sirinvaravong N, Lo KB, Patil S, Patel B et al. Leſt ventricular thrombosis in acute anterior myocardial infarction: Evaluation of hospital mortality, thromboembolism, and bleeding. Clinical Cardiology. 2018;41(10):1289–96. DOI: 10.1002/clc.23039
25. Jenča D, Melenovský V, Stehlik J, Staněk V, Kettner J, Kautzner J et al. Heart failure aſter myocardial infarction: incidence and predictors. ESC Heart Failure. 2021;8(1):222–37. DOI: 10.1002/ehf2.13144
26. Немик Д.Б., Матюшин Г.В., Устюгов С.А. Роль шкалы SYNTAX Score в стратификации внутрибольничного риска сердечно-сосудистых осложнений и летальности у больных с инфарктом миокарда с подъемом сегмента ST. Рациональная фармакотерапия в кардиологии. 2018;14(3):324–9]. DOI: 10.20996/1819-6446-2018-14-3-324-329
27. Тарасов Р.С., Ганюков В.И., Вак косов К.М., Барбараш О.Л., Барбараш Л.С. Резидуальный SYNTAX в прогнозировании отдаленных результатов эндоваскулярной реваскуляризации у больных инфарктом миокарда с элевацией сегмента ST при многососудистом поражении коронарного русла. Кардиоваскулярная терапия и профилактика. 2016;15(5):33-8]. DOI: 10.15829/1728-8800-2016-5-33-38
28. Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer J-C, Erne P et al. Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock. Annals of Internal Medicine. 2008;149(9):618–26. DOI: 10.7326/0003-4819-149-9-200811040-00005
29. Kawecki D, Morawiec B, Gąsior M, Wilczek K, Nowalany-Kozielska E, Gierlotka M. Annual Trends in Total Ischemic Time and One-Year Fatalities: The Paradox of STEMI Network Performance Assessment. Journal of Clinical Medicine. 2019;8(1):78. DOI: 10.3390/jcm8010078
30. Бессонов И.С., Кузнецов В.А., Горбатенко Е.А., Дьякова А.О., Сапожников С.С. Влияние общего времени ишемии миокарда на результаты лечения пациентов с острым инфарктом миокарда с подъемом сегмента ST на электрокардиограмме. Кардиология. 2021;61(2):40–6]. DOI: 10.18087/cardio.2021.2.n1314
31. Khalid U, Jneid H, Denktas AE. The relationship between total ischemic time and mortality in patients with STEMI: every second counts. Cardiovascular Diagnosis and Therapy. 2017;7(S2):S119–24. DOI: 10.21037/cdt.2017.05.10
32. Denktas AE, Anderson HV, McCarthy J, Smalling RW. Total Ischemic Time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care. JACC: Cardiovascular Interventions. 2011;4(6):599–604. DOI: 10.1016/j.jcin.2011.02.012
33. Kim HK, Jeong MH, Ahn Y, Chae SC, Kim YJ, Hur SH et al. Relationship between time to treatment and mortality among patients undergoing primary percutaneous coronary intervention according to Korea Acute Myocardial Infarction Registry. Journal of Cardiology. 2017;69(1):377–82. DOI: 10.1016/j.jjcc.2016.09.002
34. Shiomi H, Nakagawa Y, Morimoto T, Furukawa Y, Nakano A, Shirai S et al. AS-015: Total Ischemic Time and Primary PCI: Optimal Time Period from Symptom-onset to Reperfusion Therapy. The American Journal of Cardiology. 2012;109(7): S7. DOI: 10.1016/j.amjcard.2012.01.012
35. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Maz
36. zone T et al. Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117(12):1610–9. DOI: 10.1161/CIRCULATIONAHA.107.188629
37. Koracevic GP. Proposal of a New Approach to Study and Categorize Stress Hyperglycemia in Acute Myocardial Infarction. The Journal of Emergency Medicine. 2016;51(1):31–6. DOI: 10.1016/j.jemermed.2015.03.047
38. Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon aſter percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart Journal. 2018;70(Suppl 3):S406–18. DOI: 10.1016/j.ihj.2018.01.032
39. Kloner RA, King KS, Harrington MG. No-reflow phenomenon in the heart and brain. American Journal of Physiology-Heart and Circulatory Physiology. 2018;315(3):H550–62. DOI: 10.1152/ajpheart.00183.2018
40. O’Neill WW, Schreiber T, Wohns DHW, Rihal C, Naidu SS, Civitello AB et al. The Current Use of Impella® 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry. Journal of Interventional Cardiology. 2014;27(1):1–11. DOI: 10.1111/joic.12080
41. Барбараш О.Л., Кашталап В.В., Кочергина А.М., Леонова В.О., Эрлих А.Д. Ведение пациентов с острым коронарным синдромом с подъемом сегмента ST в инвазивных стационарах. Результаты регистрового исследования РЕКОРД-3. Фундаментальная и клиническая медицина. 2016;1(3):6-13
42. Сагайдак О.В., Ощепкова Е.В., Чазова И.Е. Особенности лечения кардиогенного шока у пациентов с острым коронарным синдромом по данным Федерального регистра. Терапевтический архив. 2019;91(9):47–52]. DOI: 10.26442/00403660.2019.09.000317
43. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine. 2017;377(25):2419–32. DOI: 10.1056/NEJMoa1710261